Biosimilars: US FDA Expecting More Applications, Fewer Applicants

 
• By Nielsen Hobbs

Preparing biosimilar applications still takes as much time as it would for an original BLA, FDA says.

Projection screen on the stage.
US FDA's biosimilar projections usually aren't this dramatic, but they do tell a story.

More from Biosimilars

More from Biosimilars & Generics